Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors

Eun Jig Lee, Leonard M. Anderson, Bayar Thimmapaya, J. Larry Jameson

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Pituitary adenomas cause clinical manifestations because of mass effects and excess hormone production. This group of tumors represents a tractable target for gene therapy because they are rarely metastatic and because reductions in tumor size and function, in addition to those achieved after surgery, may be of clinical benefit. In this report we describe a strategy for targeting the expression of toxic genes to pituitary cells using adenoviral vectors. Pituitary hormone promoters (human GH or glycoprotein hormone α-subunit) were used to express either a marker gene [β- galactosidase (β-gal)] or a toxic gene [herpes simplex virus thymidine kinase (TK)]. In GH-producing GH3 cells and in α-subunit-producing pituitary tumor cell lines, recombinant adenoviruses containing either the α-subunit promoter (AdαGal; AdαTK) or the GH promoter (AdGHGal; AdGHTK) were expressed at high levels. Using histological studies and assays for β- gal activity, expression was shown to persist for at least 21 days, and it was relatively selective for pituitary cell lines. Cytotoxicity studies were performed using the TK-containing vectors and treatment with ganciclovir. Both AdGHTK and AdαTK caused greater than 95% cytotoxicity of GH3 and αT3 cells, respectively, at a viral dose (multiplicity of infection, 5 plaque- forming units/cell) that induced minimal toxicity using control viruses. Little cellular toxicity was seen using a nonpituitary cell line (T47D breast tumor cells). The AdGHTK virus also caused marked reduction in the size of GH3 cell tumors that were propagated in nude mice. These studies suggest that adenoviral vectors carrying human pituitary gland specific promoters may be useful for developing gene therapy strategies for the treatment of pituitary adenomas.

Original languageEnglish
Pages (from-to)786-794
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume84
Issue number2
DOIs
Publication statusPublished - 1999 Feb 17

Fingerprint

Gene therapy
Pituitary Hormones
Poisons
Pituitary Neoplasms
Adenoviridae
Genetic Therapy
Tumors
Genes
Gene Expression
Viruses
Cells
Thymidine Kinase
Cytotoxicity
Toxicity
Galactosidases
Hormones
Cell Line
Neoplasms
Ganciclovir
Pituitary Gland

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

@article{755b2c7bc4c641098793fd68f4d271e3,
title = "Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors",
abstract = "Pituitary adenomas cause clinical manifestations because of mass effects and excess hormone production. This group of tumors represents a tractable target for gene therapy because they are rarely metastatic and because reductions in tumor size and function, in addition to those achieved after surgery, may be of clinical benefit. In this report we describe a strategy for targeting the expression of toxic genes to pituitary cells using adenoviral vectors. Pituitary hormone promoters (human GH or glycoprotein hormone α-subunit) were used to express either a marker gene [β- galactosidase (β-gal)] or a toxic gene [herpes simplex virus thymidine kinase (TK)]. In GH-producing GH3 cells and in α-subunit-producing pituitary tumor cell lines, recombinant adenoviruses containing either the α-subunit promoter (AdαGal; AdαTK) or the GH promoter (AdGHGal; AdGHTK) were expressed at high levels. Using histological studies and assays for β- gal activity, expression was shown to persist for at least 21 days, and it was relatively selective for pituitary cell lines. Cytotoxicity studies were performed using the TK-containing vectors and treatment with ganciclovir. Both AdGHTK and AdαTK caused greater than 95{\%} cytotoxicity of GH3 and αT3 cells, respectively, at a viral dose (multiplicity of infection, 5 plaque- forming units/cell) that induced minimal toxicity using control viruses. Little cellular toxicity was seen using a nonpituitary cell line (T47D breast tumor cells). The AdGHTK virus also caused marked reduction in the size of GH3 cell tumors that were propagated in nude mice. These studies suggest that adenoviral vectors carrying human pituitary gland specific promoters may be useful for developing gene therapy strategies for the treatment of pituitary adenomas.",
author = "Lee, {Eun Jig} and Anderson, {Leonard M.} and Bayar Thimmapaya and Jameson, {J. Larry}",
year = "1999",
month = "2",
day = "17",
doi = "10.1210/jc.84.2.786",
language = "English",
volume = "84",
pages = "786--794",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

Targeted expression of toxic genes directed by pituitary hormone promoters : A potential strategy for adenovirus-mediated gene therapy of pituitary tumors. / Lee, Eun Jig; Anderson, Leonard M.; Thimmapaya, Bayar; Jameson, J. Larry.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 84, No. 2, 17.02.1999, p. 786-794.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeted expression of toxic genes directed by pituitary hormone promoters

T2 - A potential strategy for adenovirus-mediated gene therapy of pituitary tumors

AU - Lee, Eun Jig

AU - Anderson, Leonard M.

AU - Thimmapaya, Bayar

AU - Jameson, J. Larry

PY - 1999/2/17

Y1 - 1999/2/17

N2 - Pituitary adenomas cause clinical manifestations because of mass effects and excess hormone production. This group of tumors represents a tractable target for gene therapy because they are rarely metastatic and because reductions in tumor size and function, in addition to those achieved after surgery, may be of clinical benefit. In this report we describe a strategy for targeting the expression of toxic genes to pituitary cells using adenoviral vectors. Pituitary hormone promoters (human GH or glycoprotein hormone α-subunit) were used to express either a marker gene [β- galactosidase (β-gal)] or a toxic gene [herpes simplex virus thymidine kinase (TK)]. In GH-producing GH3 cells and in α-subunit-producing pituitary tumor cell lines, recombinant adenoviruses containing either the α-subunit promoter (AdαGal; AdαTK) or the GH promoter (AdGHGal; AdGHTK) were expressed at high levels. Using histological studies and assays for β- gal activity, expression was shown to persist for at least 21 days, and it was relatively selective for pituitary cell lines. Cytotoxicity studies were performed using the TK-containing vectors and treatment with ganciclovir. Both AdGHTK and AdαTK caused greater than 95% cytotoxicity of GH3 and αT3 cells, respectively, at a viral dose (multiplicity of infection, 5 plaque- forming units/cell) that induced minimal toxicity using control viruses. Little cellular toxicity was seen using a nonpituitary cell line (T47D breast tumor cells). The AdGHTK virus also caused marked reduction in the size of GH3 cell tumors that were propagated in nude mice. These studies suggest that adenoviral vectors carrying human pituitary gland specific promoters may be useful for developing gene therapy strategies for the treatment of pituitary adenomas.

AB - Pituitary adenomas cause clinical manifestations because of mass effects and excess hormone production. This group of tumors represents a tractable target for gene therapy because they are rarely metastatic and because reductions in tumor size and function, in addition to those achieved after surgery, may be of clinical benefit. In this report we describe a strategy for targeting the expression of toxic genes to pituitary cells using adenoviral vectors. Pituitary hormone promoters (human GH or glycoprotein hormone α-subunit) were used to express either a marker gene [β- galactosidase (β-gal)] or a toxic gene [herpes simplex virus thymidine kinase (TK)]. In GH-producing GH3 cells and in α-subunit-producing pituitary tumor cell lines, recombinant adenoviruses containing either the α-subunit promoter (AdαGal; AdαTK) or the GH promoter (AdGHGal; AdGHTK) were expressed at high levels. Using histological studies and assays for β- gal activity, expression was shown to persist for at least 21 days, and it was relatively selective for pituitary cell lines. Cytotoxicity studies were performed using the TK-containing vectors and treatment with ganciclovir. Both AdGHTK and AdαTK caused greater than 95% cytotoxicity of GH3 and αT3 cells, respectively, at a viral dose (multiplicity of infection, 5 plaque- forming units/cell) that induced minimal toxicity using control viruses. Little cellular toxicity was seen using a nonpituitary cell line (T47D breast tumor cells). The AdGHTK virus also caused marked reduction in the size of GH3 cell tumors that were propagated in nude mice. These studies suggest that adenoviral vectors carrying human pituitary gland specific promoters may be useful for developing gene therapy strategies for the treatment of pituitary adenomas.

UR - http://www.scopus.com/inward/record.url?scp=0032979226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032979226&partnerID=8YFLogxK

U2 - 10.1210/jc.84.2.786

DO - 10.1210/jc.84.2.786

M3 - Article

C2 - 10022454

AN - SCOPUS:0032979226

VL - 84

SP - 786

EP - 794

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -